Zentalis Pharmaceuticals Reports Pricing Of Offering Of 11.03M Shares At $22.66 Per Share For Total Gross Proceeds Of $250M
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharmaceuticals announced the pricing of its offering of 11.03 million shares at $22.66 per share, raising $250 million in gross proceeds. The offering is expected to close on June 20, 2023, and the proceeds will be used to fund ongoing and planned clinical trials, working capital, and other general corporate purposes.
June 15, 2023 | 10:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zentalis Pharmaceuticals' stock offering of 11.03 million shares at $22.66 per share will raise $250 million, which will be used for clinical trials and general corporate purposes.
The stock offering will provide Zentalis Pharmaceuticals with additional capital to fund ongoing and planned clinical trials, working capital, and other general corporate purposes. This news is directly related to the company and its financial position, but the short-term impact on the stock price is uncertain as the market may have already priced in the offering.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100